You are here

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies

Authors

  • Guillem Pascual-Pasto Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Brendan McIntyre Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Rawan Shraim Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USADepartment of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Samantha N Buongervino Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Amy K Erbe Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Doncho V Zhelev Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Shakhnozakhon Sadirova Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Anna M Giudice Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Daniel Martinez Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Laura Garcia-Gerique Immunology, Microenvironment and Metastasis Program, Wistar Institute, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Dimiter S Dimitrov Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA PubMed articlesGoogle scholar articles
  • Paul M Sondel Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USADepartment of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, USA PubMed articlesGoogle scholar articles
  • Kristopher R Bosse Division of Oncology and Center for Childhood Cancer Research, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USADepartment of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA PubMed articlesGoogle scholar articles

Citation

Pascual-Pasto G, McIntyre B, Shraim R, et al
GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
Journal for ImmunoTherapy of Cancer 2022;10:e004704. doi: 10.1136/jitc-2022-004704
Online issue publication 
October 18, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.